Key Quantitative Figures

  • Total options granted: 295,000 (Two Lakh Ninety-Five Thousand)
  • Each option convertible into: 1 equity share of face value ₹1 each
  • Total shares covered: 295,000 equity shares
  • Exercise price: ₹43 per option/share
  • Market reference: BSE Limited last closing market price dated October 28, 2026
  • Discount applied: 93.42% from market price

Dates of Action

  • Committee meeting date: October 29, 2026
  • Grant date: October 29, 2026

Parties Involved

  • Issuing company: Bliss GVS Pharma Limited
  • Approving authority: Nomination and Remuneration Committee
  • Recipients: Eligible employees of the Company
  • Regulatory references: SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Vesting Schedule

The options vest in four equal installments:

  • 25% after 12 months from grant date
  • 25% after 24 months from grant date
  • 25% after 36 months from grant date
  • 25% after 48 months from grant date

Exercise Terms

  • Minimum vesting period: 1 year between grant and vesting
  • Exercise period: 6 months from date of vesting for each installment
  • Shares subject to lock-in: 6 months from date of allotment of equity shares

Pricing Rationale

The exercise price of ₹43 was determined to bring uniformity in the exercise price of earlier options granted by the Company, based on the BSE Limited last closing market price dated October 28, 2026, after deducting 93.42% discount.

Current Status

  • Options vested: Not applicable (new grant)
  • Options exercised: Not applicable
  • Money realized: Not applicable
  • Shares issued: Not applicable
  • Options lapsed: Not applicable
  • Terms variation: Not applicable
  • Diluted EPS impact: Not applicable